| Product Name | Sacubitrilat-13C4 |
| Product Code | DA-S146-a |
| Chemical name | Sacubitrilat-13C4 |
| Synonyms | Desethyl Sacubitril-13C4; (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic Acid-13C4; (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic Acid-13C4; LBQ 657-13C4; LBQ657-13C4 Desethyl Sacubitril=13C4; Sacubitrilat=13C4; [S-(R*,S*)]-γ-[(3-Carboxy-1-oxopropyl)amino]-α-methyl-[1,1'-Biphenyl]-4-pentanoic Acid-13C4; |
| Impurity | NA |
| CAS Number | NA |
| Alternate CAS # | NA |
| Molecular form | C1813C4H25NO5 |
| Appearance | NA |
| Melting Point | NA |
| Mol. Weight | 387.41 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | stable isotopes |
| Boiling Point | NA |
| Applications | Desethyl Sacubitril-13C4 is the labelled, deuterated version of Desethyl Sacubitril which is an impurity in the synthesis of Sacubitril, an antihypertensive drug used in combination with valsartan. The combination drug, valsartan/sacubitril, known during trials as LCZ696 and marketed under the brand name, Entresto, is a treatment for heart failure. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
